Daily tadalafil and vardenafil chews are a compounded approach to erectile dysfunction (ED) that combines two phosphodiesterase type 5 (PDE5) inhibitors with vitamins D3 and K2. The formulation is pharmacologically plausible, but plausibility is not the same as definitive clinical proof. Tadalafil 5 mg has extensive evidence as a once-daily ED treatment; vardenafil is an established on-demand PDE5 inhibitor; and early combination studies suggest that selected men who do not respond adequately to one drug may benefit from supervised dual therapy. Evidence for the complete four-ingredient formulation, however, remains limited. Understanding what is known—and what is not—helps patients and prescribers make safer decisions.
How PDE5 Inhibitors Support an Erection
An erection begins with sexual stimulation in the brain and peripheral nerves. Nitric oxide released in penile tissue activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP). This signal relaxes smooth muscle in the corpora cavernosa, allowing arterial inflow to rise while expanding tissue compresses the veins that normally drain the penis.
PDE5 breaks down cGMP. Tadalafil and vardenafil inhibit that enzyme, so the signal produced after sexual stimulation persists longer. They do not create sexual desire, trigger an automatic erection, or correct every cause of ED. Severe arterial disease, nerve injury, major hormonal deficiency, medication effects, pelvic surgery, depression, relationship distress, and inadequate stimulation can all limit response even when PDE5 is inhibited.
The two drugs act at the same molecular target but have different pharmacokinetic profiles. Tadalafil has a half-life of approximately 17.5 hours, supporting sustained exposure and once-daily dosing. Vardenafil has a shorter half-life, generally around four to five hours, and is conventionally used before anticipated sexual activity. A combined formulation is therefore intended to pair a stable tadalafil background with a shorter vardenafil component. That rationale should not be described as two independent erection mechanisms: both drugs inhibit PDE5, and their effects and adverse effects can overlap.
Daily Tadalafil and Vardenafil: What the Evidence Shows
Daily tadalafil 5 mg has the stronger evidence base. A meta-analysis of six randomized trials involving 1,596 men found that at least six months of tadalafil 5 mg daily improved the erectile-function domain of the International Index of Erectile Function (IIEF-EF) versus placebo, with a pooled mean difference of 3.09 points [1]. A 2024 placebo-controlled study of tadalafil 5 mg delivered as an oral dispersible film also reported improved IIEF scores, providing useful evidence that a non-tablet oral formulation can deliver clinically active tadalafil [2]. These data do not automatically validate every compounded chew, because absorption, excipients, manufacturing controls, and bioavailability can differ.
Combination evidence is newer and much smaller. In a 2026 prospective pilot study, 62 men who had not responded to repeated tadalafil or vardenafil monotherapy received tadalafil 5 mg daily plus vardenafil 10 mg on demand for 12 weeks. Mean IIEF-5 increased from 11.2 to 18.9, and 74% achieved an improvement of at least five points [3]. Reported adverse effects were mild and transient, but the study was preliminary, lacked a placebo comparison, and evaluated vardenafil on demand—not both drugs taken together every day.
A 2024 conference study similarly evaluated daily tadalafil 5 mg plus on-demand sildenafil in 40 men with prior PDE5-inhibitor nonresponse and reported improvement in erection scores with generally minor adverse effects [4]. It supports further research into supervised long-acting plus short-acting PDE5 inhibition, but a small abstract cannot establish long-term safety, superiority, or an optimal regimen.
Contemporary European guidance continues to recommend PDE5 inhibitors as first-line drug therapy while emphasizing correct use, risk-factor modification, and individualized assessment [5]. Dual PDE5 inhibition is not a routine guideline standard. It is better understood as a clinician-directed option for carefully selected patients, supported by emerging rather than conclusive evidence.
Why Vitamins D3 and K2 May Be Included
Vitamin D participates in endothelial, metabolic, inflammatory, bone, and muscle physiology. Observational research has often found lower vitamin D levels in men with more severe or arteriogenic ED, but association does not prove that deficiency causes ED. Low vitamin D may also be a marker of obesity, limited outdoor activity, chronic illness, or poorer cardiometabolic health.
A 2023 systematic review identified eight clinical trials of vitamin D and sexual function, including four studies in men. The authors reported generally favorable findings but emphasized the small, heterogeneous evidence base and the need for larger trials [6]. More recent reviews have reached a cautious conclusion: low vitamin D status may accompany ED, yet supplementation has not consistently improved erectile outcomes in randomized studies. Correcting a documented deficiency may support general health; vitamin D should not be presented as an established ED drug or a substitute for vascular evaluation.
Vitamin K2 is involved in activating proteins that regulate calcium handling in bone and vascular tissue. That biology has generated interest in cardiovascular health, but there is no robust clinical evidence that K2 independently improves erections or enhances a PDE5 inhibitor. Its presence should therefore be interpreted as nutritional support rather than a proven erectile-function mechanism.
Vitamin safety still matters. Excess vitamin D can cause hypercalcemia, kidney stones, confusion, weakness, or kidney injury. Vitamin K can interact with warfarin and related vitamin K antagonist anticoagulants. Patients should disclose all supplements and medications during medical review rather than assuming that vitamins are automatically risk-free.
Who May Be Considered—and Who Should Avoid It
A physician may consider a daily regimen for a man with recurrent ED who values less medication planning, has no nitrate exposure, and is medically appropriate for sexual activity and PDE5 inhibition. A combined formulation may be discussed when a single PDE5 inhibitor has produced an incomplete response despite correct use. Before escalating therapy, clinicians should verify the diagnosis, dose, timing, stimulation, adherence, alcohol intake, meal effects, and the number of properly attempted doses.
The evaluation should also look beyond the prescription. Persistent ED can be an early marker of hypertension, diabetes, dyslipidemia, obesity, sleep apnea, or cardiovascular disease. A typical assessment includes medical and sexual history, blood pressure, medication review, focused examination, glucose or A1c, lipids, and morning testosterone when clinically indicated. New ED accompanied by exertional chest pain, breathlessness, or reduced exercise tolerance requires cardiovascular evaluation rather than empiric dose escalation.
PDE5 inhibitors must not be used with nitrates such as nitroglycerin or isosorbide because the combination can cause a dangerous fall in blood pressure. Riociguat is also contraindicated. Caution is required with alpha blockers, antihypertensives, substantial alcohol intake, severe liver or kidney disease, recent stroke or myocardial infarction, unstable cardiovascular disease, retinal disorders, and drugs that strongly inhibit CYP3A4.
Vardenafil has an additional cardiac consideration: it can prolong the QT interval and is generally avoided in men with congenital long-QT syndrome or those taking certain antiarrhythmic drugs. A clinician must assess whether the combined exposure is appropriate; patients should never add tadalafil, sildenafil, vardenafil, or another ED medication to the regimen on their own.
How to Use a Prescribed Chew Safely
The product should be taken exactly as prescribed, at a consistent time and no more frequently than directed. The chew is swallowed after chewing; it is not the same as a sublingual medicine unless the dispensing instructions specifically say otherwise. Sexual stimulation remains necessary. Because tadalafil accumulates toward steady state over several days, the experience may differ between the first dose and continued use.
Common PDE5-inhibitor adverse effects include headache, facial flushing, nasal congestion, indigestion, dizziness, and back or muscle discomfort. Combining agents that share a target may increase exposure-related effects, even when each dose appears familiar in isolation. Patients should contact the prescribing clinician if effects are persistent, troublesome, or associated with symptomatic low blood pressure.
An erection lasting four hours or longer requires emergency care. Sudden loss of vision or hearing also warrants urgent evaluation and discontinuation pending medical advice. Chest pain during sexual activity is an emergency; a patient who has taken a PDE5 inhibitor should tell emergency personnel because nitrates may be unsafe for a period after use. Tadalafil's long half-life makes that disclosure especially important.
Treatment response should be reviewed rather than assumed. Useful follow-up questions include whether erections are firmer and sustainable, whether adverse effects occur, whether spontaneity or confidence has improved, and whether blood pressure, glucose, sleep, smoking, weight, and exercise need attention. More medication is not always the answer. Counseling, pelvic-floor rehabilitation, vacuum devices, injectable therapy, or specialist evaluation may be more appropriate when the dominant cause is psychological, neurologic, structural, or severe vascular disease.
Conclusion
The evidence supporting daily tadalafil is mature; the evidence supporting vardenafil monotherapy is well established; and early studies of supervised dual PDE5 inhibition are encouraging in selected nonresponders. The evidence is not yet strong enough to say that a tadalafil–vardenafil combination is routinely superior to optimized monotherapy, and clinical data on added vitamins remain limited. Safe use depends on prescription review, cardiovascular screening, medication reconciliation, realistic expectations, and follow-up.
If you're exploring clinically-formulated options, OnyxMD EPIQ CHEWS offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. More evidence-based men's health articles are available in the blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Zhou Z, Chen H, Wu J, et al. Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials. Translational Andrology and Urology. 2020;9(3):1405-1414. doi:10.21037/tau-19-809
Motawi AT, GamalEl Din SF, Meatmed EM, et al. Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction: a comparative placebo-controlled study. International Urology and Nephrology. 2024;56:2531-2537. doi:10.1007/s11255-024-04003-x
Arian I, Dumbraveanu I, Creciun M, et al. Combined use of tadalafil and vardenafil in men with erectile dysfunction non-responsive to monotherapy with a single PDE5 inhibitor: clinical rationale and preliminary outcomes. The Journal of Sexual Medicine. 2026;23(Supplement 4):qdag118.681. doi:10.1093/jsxmed/qdag118.681
Jamali M, Chmitah T, Bahri A, et al. Efficiency and safety of combining long-acting and short-acting PDE5 inhibitors. The Journal of Sexual Medicine. 2024;21(Supplement 2):qdae002.166. doi:10.1093/jsxmed/qdae002.166
Salonia A, Boeri L, Capogrosso P, et al. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. European Urology. 2025;88(1):76-102. EAU guideline summary
Darooneh T, Ghasemi V, Roozbeh N, et al. The effect of vitamin D on sexual function: a systematic review. Nutrire. 2023;48:33. doi:10.1186/s41110-023-00221-y
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.